Live Quote · OTCMYMXHealthcare· Biotechnology

Mymetics Corporation

$0.00 0.00%(+$0.00)
TickerSpark Score
44/100
Weak
73
Valuation
35
Profitability
60
Growth
24
Health
30
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MYMX research report →

52-Week Range50% of range
Low
$0.00
Current
$0.00
High
$0.00
Company Overviewwww.mymetics.com

About the company

Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent.

CEO
Ronald Kempers
IPO
1999
Employees
2
HQ
Epalinges, CH

Price Chart

+0.00% · this period
$0.00$0.00$0.00Jul 02Dec 31Jul 02
Valuation
Market Cap
$46
P/E
-0.02
P/S
0.01
P/B
-0.00
EV/EBITDA
-36.02
Div Yield
0.00%
Profitability
Gross Margin
-47966.67%
Op Margin
-58166.67%
Net Margin
-160166.67%
ROE
7.69%
ROIC
-24.57%
Growth & Income
Revenue
$3.00K · 0.00%
Net Income
$-4,805,000 · -1.59%
EPS
$-0.02 · 32.77%
Op Income
$-1,745,000
FCF YoY
1.11%
Performance & Tape
52W High
$0.00
52W Low
$0.00
50D MA
$0.00
200D MA
$0.00
Beta
2.13
Avg Volume
1

Get TickerSpark's AI analysis on MYMX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Apr 9, 15KEMPERS Ronald Hugo Gerardother5,000,000
Jan 31, 06Round Enterprises, Ltd.other0
Jan 31, 06Round Enterprises, Ltd.other0
Oct 4, 13Fleury Sylvainother800,000
Dec 31, 09Fleury Sylvainother350,000
Jun 18, 07Fleury Sylvainother0
Jun 17, 10Stegmann Antonius Johannesother4,000,000
Jun 17, 10Stegmann Antonius Johannesother150,000
Dec 27, 13KEMPERS Ronald Hugo Gerardsell3,000,000
Dec 27, 13KEMPERS Ronald Hugo Gerardother3,000,000
Coverage · MYMX

Our MYMX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on MYMX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate MYMX report →
Internal Compare

Similar companies

Peers in the same neighborhood.